FindTrial
Sign In

Low dose dexmedetomidine as an adjuvant for Rremifentanil-based controlled hypotension for tympanoplasty

Low dose dexmedetomidine as an adjuvant for Rremifentanil-based controlled hypotension for tympanoplasty

Status
Active, not recruiting
Phases
Unknown
Study type
Interventional
Source
ChiCTR
Registry ID
ChiCTR-TRC-14005167
Enrollment
Unknown
Registered
2014-08-30
Start date
2014-08-18
Completion date
Unknown
Last updated
2017-04-18

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

tympanoplasty

Interventions

DR:dexmedetomidine plus remifentanil to controlled hypotension
R:use remifentanil to controlled hypotension

Sponsors

Shanghai Eye, Ear, Nose, and Throat Hospital, Fudan University
Lead Sponsor

Eligibility

Sex/Gender
All
Age
18 Years to 70 Years

Inclusion criteria

Inclusion criteria: Eighty patients ASA I or II aged 18-70 years scheduled for middle ear operation

Exclusion criteria

Exclusion criteria: Exclude cardiovascular and cerebrovascular diseases such as hypertension, coronary disease, myocardial infarction, cerebral infarction, cardiac insufficiency, valvular disease, myocardiosis and so on. Discharge LMA to endotracheal intubation. The operating time is shorter than one hour or more than three hours.

Design outcomes

Primary

MeasureTime frame
visual field;—

Secondary

MeasureTime frame
time to recovery;pain VAS scale;agitation;postoperative Nausea and Vomiting;Dose of remifentanil;—

Countries

China

Contacts

Public ContactXia Shen
shenxia@eentanesthesia.com+86 13611874118

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026